- Home
- BYM vs CDXS Comparison
BYM vs CDXS Comparison
Compare BYM & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYM
- CDXS
- Stock Information
- Founded
- BYM 2002
- CDXS 2002
- Country
- BYM United States
- CDXS United States
- Employees
- BYM N/A
- CDXS N/A
- Industry
- BYM Investment Managers
- CDXS Major Chemicals
- Sector
- BYM Finance
- CDXS Industrials
- Exchange
- BYM Nasdaq
- CDXS Nasdaq
- Market Cap
- BYM 279.9M
- CDXS 230.3M
- IPO Year
- BYM N/A
- CDXS 2010
- Fundamental
- Price
- BYM $10.84
- CDXS $2.49
- Analyst Decision
- BYM
- CDXS Buy
- Analyst Count
- BYM 0
- CDXS 2
- Target Price
- BYM N/A
- CDXS $11.00
- AVG Volume (30 Days)
- BYM 60.2K
- CDXS 1.1M
- Earning Date
- BYM 01-01-0001
- CDXS 05-01-2025
- Dividend Yield
- BYM 4.49%
- CDXS N/A
- EPS Growth
- BYM N/A
- CDXS N/A
- EPS
- BYM N/A
- CDXS N/A
- Revenue
- BYM N/A
- CDXS $59,345,000.00
- Revenue This Year
- BYM N/A
- CDXS $12.62
- Revenue Next Year
- BYM N/A
- CDXS $22.11
- P/E Ratio
- BYM N/A
- CDXS N/A
- Revenue Growth
- BYM N/A
- CDXS N/A
- 52 Week Low
- BYM $9.30
- CDXS $2.42
- 52 Week High
- BYM $11.77
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- BYM 43.75
- CDXS 36.23
- Support Level
- BYM $10.68
- CDXS $2.43
- Resistance Level
- BYM $10.90
- CDXS $3.04
- Average True Range (ATR)
- BYM 0.12
- CDXS 0.21
- MACD
- BYM 0.00
- CDXS 0.04
- Stochastic Oscillator
- BYM 50.00
- CDXS 8.78
Stock Price Comparison Chart: BYM vs CDXS
About BYM Blackrock Municipal Income Quality Trust of Beneficial Interest
Blackrock Municipal Income Quality Trust is a closed-end municipal bond fund. Its investment objective is to provide current income exempt from U.S. federal income taxes, including the alternative minimum tax. The trust invests in various sectors such as transportation, utilities, health, education, corporate, housing, and others.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.